Liver Cancer Trial Results
Sorafenib for Advanced Liver Cancer Increases Survival
(Posted: 06/13/2007, Updated: 07/30/2008) - The targeted drug sorafenib (Nexavar®) has improved the survival of patients with advanced liver cancer, according to the July 24, 2008, New England Journal of Medicine.
Sorafenib Increases the Risk of High Blood Pressure
(Posted: 04/02/2008) - Combined data from nine studies showed that patients receiving the standard amount of sorafenib (Nexavar®), an anticancer drug that interferes with a tumor's blood supply, run a significant risk of high blood pressure (hypertension), according to the February 2008 Lancet Oncology.
(Posted: 06/13/2007, Updated: 07/30/2008) - The targeted drug sorafenib (Nexavar®) has improved the survival of patients with advanced liver cancer, according to the July 24, 2008, New England Journal of Medicine.
Sorafenib Increases the Risk of High Blood Pressure
(Posted: 04/02/2008) - Combined data from nine studies showed that patients receiving the standard amount of sorafenib (Nexavar®), an anticancer drug that interferes with a tumor's blood supply, run a significant risk of high blood pressure (hypertension), according to the February 2008 Lancet Oncology.